Biomedical Engineering Reference
In-Depth Information
the nature of binding specificity with receptors. Biochemistry
46, 12238-12247.
157. Hamdy NA. (2005) Osteoprotegerin as a potential therapy for
osteoporosis. Curr. Osteoporos. Rep. 3, 121-125.
158. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, et al.
(2010) Double antiangiogenic protein, DAAP, targeting
VEGF-A and angiopoietins in tumor angiogenesis, metasta-
sis, and vascular leakage. Cancer Cell 18, 171-184.
159. Sengle G, Ono RN, Sasaki T, Sakai LY. (2011) Prodomains of
transforming growth factor beta (TGFbeta) superfamily
members specify different functions: extracellular matrix
interactions and growth factor bioavailability. J. Biol.
Chem. 286, 5087-5099.
160. Mazerbourg S, Hsueh AJ. (2006) Genomic analyses facilitate
identification of receptors and signalling pathways for growth
differentiation factor 9 and related orphan bone morphoge-
netic protein/growth differentiation factor ligands. Hum.
Reprod. Update 12, 373-383.
161. Mazerbourg S, Sangkuhl K, Luo CW, Sudo S, Klein C, Hsueh
AJ. (2005) Identification of receptors and signaling pathways
for orphan bone morphogenetic protein/growth differentia-
tion factor ligands based on genomic analyses. J. Biol. Chem.
280, 32122-32132.
162. Nickel J, Sebald W, Groppe JC, Mueller TD. (2009) Intrica-
cies of BMP receptor assembly. Cytokine Growth Factor
Rev. 20, 367-377.
163. Canalis E, Economides AN, Gazzerro E. (2003) Bone mor-
phogenetic proteins, their antagonists, and the skeleton.
Endocr. Rev. 24, 218-235.
164. Zakin L, De Robertis EM. (2009) Extracellular regulation of
BMP signaling. Curr. Biol. 20, R89-R92.
165. Umulis D, O'Connor MB, Blair SS. (2009) The extracellular
regulation of bone morphogenetic protein signaling. Devel-
opment 136, 3715-3728.
166. Rider CC, Mulloy B. (2011) Bone morphogenetic protein and
growth differentiation factor cytokine families and their
protein antagonists. Biochem. J. 429, 1-12.
167. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP,
Nicholl JK, et al. (1995) Identification and characterization of
a new member of the TNF family that induces apoptosis.
Immunity 3, 673-682.
168. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silver-
man C, et al. (1998) Osteoprotegerin is a receptor for the
cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367.
169. Kostenuik PJ. (2005) Osteoprotegerin and RANKL regulate
bone resorption, density, geometry and strength. Curr. Opin.
Pharmacol. 5, 618-625.
170. Stohl W, Scholz JL, Cancro MP. (2011) Targeting BLyS in
rheumatic disease: the sometimes-bumpy road from bench to
bedside. Curr. Opin. Rheumatol. 23, 305-310.
171. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE,
Halpern WG, et al. (2003) Generation and characterization of
LymphoStat-B, a human monoclonal antibody that antago-
nizes the bioactivities of B lymphocyte stimulator. Arthritis
Rheum. 48, 3253-3265.
172. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French
DM, et al. (2002) BAFF/BLyS receptor 3 binds the B cell
survival factor BAFF ligand through a discrete surface
loop and promotes processing of NF-kappaB2. Immunity
17, 515-524.
173. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L,
Dobles M, et al. (2008) TACI, unlike BAFF-R, is solely
activated by oligomeric BAFF and APRIL to support survival
of activated B cells and plasmablasts. Blood 111, 1004-1012.
174. Mackay F, Schneider P. (2008) TACI, an enigmatic
BAFF/APRIL receptor, with new unappreciated biochemical
and biological properties. Cytokine Growth Factor Rev. 19,
263-276.
175. Mackay F, Schneider P. (2009) Cracking the BAFF code. Nat.
Rev. Immunol. 9, 491-502.
176. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, et
al. (2004) Reduced competitiveness of autoantigen-engaged
B cells due to increased dependence on BAFF. Immunity 20,
441-453.
177. Thien M, Phan TG, Gardam S, Amesbury M, Basten A,
Mackay F, et al. (2004) Excess BAFF rescues self-reactive B
cells from peripheral deletion and allows them to enter
forbidden follicular and marginal zone niches. Immunity
20, 785-798.
178. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan AK,
et al. (2004) Impaired IgA class switching in APRIL-deficient
mice. Proc. Natl. Acad. Sci. USA 101, 3903-3908.
179. Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M,
Zhong J, et al. (2006) Chronic administration of belimumab,
a BLyS antagonist, decreases tissue and peripheral blood B-
lymphocyte populations in cynomolgus monkeys: pharmaco-
kinetic, pharmacodynamic, and toxicologic effects. Toxicol.
Sci. 91, 586-599.
180. Carbonatto M, Yu P, Bertolino M, Vigna E, Steidler S, Fava L,
et al. (2008) Nonclinical safety, pharmacokinetics,
and pharmacodynamics of atacicept. Toxicol. Sci. 105,
200-210.
181. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J,
Miyagawa H, et al. (2005) Raised serum APRIL levels in
patients with systemic lupus erythematosus. Ann. Rheum.
Dis. 64, 1065-1067.
182. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W,
Wahren-Herlenius M, Trollmo C, et al. (2006) Differential
effects on BAFF and APRIL levels in rituximab-treated
patients with systemic lupus erythematosus and rheumatoid
arthritis. Arthritis Res. Ther. 8, R167.
183. Planelles L, Castillo-Gutierrez S, Medema JP, Morales-Luque
A, Merle-Beral H, Hahne M. (2007) APRIL but not BLyS
serum levels are increased in chronic lymphocytic leukemia:
prognostic relevance of APRIL for survival. Haematologica
92, 1284-1285.
184. Kimberley FC, Hahne M, Medema JP. (2009) “APRIL hath
put a spring of youth in everything”: Relevance of APRIL for
survival. J. Cell. Physiol. 218, 1-8.
185. Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas
C, et al. (2009) Serum levels of tumour necrosis factor family
members a proliferation-inducing ligand (APRIL) and B lym-
phocyte stimulator (BLyS) are inversely correlated in systemic
lupus erythematosus. Ann. Rheum. Dis. 68, 997-1002.
Search WWH ::
Custom Search